Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD19R(EQ)28zetaEGFRt+ Tn/mem cells |
Synonyms | |
Therapy Description |
CD19R(EQ)28zetaEGFRt+ Tn/mem cells consist of a preparation of CD62L-positive naive and memory T-lymphocytes engineered to express a modified CD19-targeting (CD19R(EQ)) chimeric antigen receptor (CAR) as well as CD28 and CD3-zeta signaling domains, as well as a truncated EGFR (EGFRt), which potentially induces toxicity against tumor cells expressing CD19 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD19R(EQ)28zetaEGFRt+ Tn/mem cells | CD19R(EQ)28zeta/EGFRt-expressing naive and memory T cells | CD19 Immune Cell Therapy 62 | CD19R(EQ)28zetaEGFRt+ Tn/mem cells consist of a preparation of CD62L-positive naive and memory T-lymphocytes engineered to express a modified CD19-targeting (CD19R(EQ)) chimeric antigen receptor (CAR) as well as CD28 and CD3-zeta signaling domains, as well as a truncated EGFR (EGFRt), which potentially induces toxicity against tumor cells expressing CD19 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|